180 Life Sciences Corp.
ATNF
$1.08
-$0.09-7.69%
| Weiss Ratings | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.33 | |||
| Price History | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.49% | |||
| 30-Day Total Return | -25.00% | |||
| 60-Day Total Return | -44.04% | |||
| 90-Day Total Return | -72.45% | |||
| Year to Date Total Return | -37.21% | |||
| 1-Year Total Return | -69.83% | |||
| 2-Year Total Return | -97.54% | |||
| 3-Year Total Return | -99.89% | |||
| 5-Year Total Return | -99.97% | |||
| 52-Week High % Change | -93.92% | |||
| 52-Week Low % Change | 1.89% | |||
| Price | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $17.75 | |||
| 52-Week Low Price | $1.06 | |||
| 52-Week Low Price (Date) | Mar 11, 2025 | |||
| 52-Week High Price (Date) | Oct 16, 2024 | |||
| Valuation | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.43M | |||
| Enterprise Value | 3.72M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -4.49 | |||
| Earnings Per Share Growth | -98.18% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.30 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $1.08 | |||
| Enterprise Value/EBITDA (TTM) | -0.59 | |||
| Enterprise Value/EBIT | -0.58 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 980.60K | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 507 0669 | |||
| Address | Building 4 Palo Alto, CA 94306 | |||
| Website | 180lifesciences.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -51.62% | |||
| Return on Equity | -- | |||
| Income Statement | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -6.29M | |||
| EBIT (TTM) | -6.37M | |||
| Net Income (TTM) | -3.12M | |||
| Net Income Avl. to Common (TTM) | -3.12M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 91.85% | |||
| EPS Diluted (TTM) | -4.49 | |||
| EPS Diluted Growth (Q YOY) | 96.52% | |||
| Balance Sheet | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 194.90K | |||
| Cash Per Share (Q) | $0.20 | |||
| Total Current Assets (Q) | 1.23M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 3.73M | |||
| Current Ratio (Q) | 0.192 | |||
| Book Value Per Share (Q) | $3.64 | |||
| Total Assets (Q) | 10.47M | |||
| Total Current Liabilities (Q) | 6.38M | |||
| Total Debt (Q) | 483.70K | |||
| Total Liabilities (Q) | 6.74M | |||
| Total Common Equity (Q) | 3.73M | |||
| Cash Flow | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 463.00K | |||
| Net Change in Cash (TTM) | -2.47M | |||
| Levered Free Cash Flow (TTM) | -2.01M | |||
| Cash from Operations (TTM) | -2.69M | |||
